Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience

PURPOSE: Dramatic advances in our understanding of the molecular pathophysiology of cancer, along with a rapidly expanding portfolio of molecular targeted drugs, have led to a paradigm shift toward personalized, biomarker-driven cancer treatment. Here, we report the 2-year experience of the Comprehe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JCO Precis Oncol
Hauptverfasser: Hoefflin, Rouven, Geißler, Anna-Lena, Fritsch, Ralph, Claus, Rainer, Wehrle, Julius, Metzger, Patrick, Reiser, Meike, Mehmed, Leman, Fauth, Lisa, Heiland, Dieter Henrik, Erbes, Thalia, Stock, Friedrich, Csanadi, Agnes, Miething, Cornelius, Weddeling, Britta, Meiss, Frank, von Bubnoff, Dagmar, Dierks, Christine, Ge, Isabell, Brass, Volker, Heeg, Steffen, Schäfer, Henning, Boeker, Martin, Rawluk, Justyna, Botzenhart, Elke Maria, Kayser, Gian, Hettmer, Simone, Busch, Hauke, Peters, Christoph, Werner, Martin, Duyster, Justus, Brummer, Tilman, Boerries, Melanie, Lassmann, Silke, von Bubnoff, Nikolas
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2018
Schlagworte:
Original Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446498/
https://ncbi.nlm.nih.gov/pubmed/32913998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00105
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge